ST. LOUIS, MO — Medical technology company Stereotaxis announced today its strategic vision to exceed $40 million in annual revenue by 2026, a goal reportedly underpinned by a robust manufacturing ramp and an unwavering commitment to 'product innovation.' The announcement, delivered via a press release, outlined these objectives with the confidence typically reserved for predicting the sunrise.

“We are incredibly excited about our 2026 targets, which we meticulously crafted ourselves,” stated CEO David F. Smith in a prepared statement. “Our internal modeling indicates that if we continue to innovate and manufacture things, and people buy those things, we will indeed hit our numbers. It’s a bold strategy, but one we believe in deeply.”

Industry analysts were quick to praise the company’s innovative approach to financial forecasting. “It takes real courage to just declare you’re going to make more money in the future, without necessarily detailing the granular, messy steps of how,” commented financial pundit Brenda Chen. “This kind of forward-thinking, self-fulfilling prophecy is what separates the market leaders from the companies that actually have to explain things.”

Sources close to the company suggest that the 'manufacturing ramp' involves ensuring the factory lights remain on, and 'product innovation' refers to a standing directive to 'make things better, somehow.'